The "mRNA Synthesis Raw Materials - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The global market for mRNA Synthesis Raw Materials was estimated at US$1.7 Billion in 2024 and is projected to reach US$2.0 Billion by 2030, growing at a CAGR of 2.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The rapid advancement of mRNA-based technologies has propelled the demand for high-purity and scalable raw materials essential for the synthesis of messenger RNA (mRNA). These raw materials include nucleotides, enzymes, capping reagents, and lipid nanoparticles (LNPs), all of which play a crucial role in ensuring the stability, efficacy, and manufacturability of mRNA therapeutics and vaccines. The unprecedented success of mRNA COVID-19 vaccines demonstrated the transformative potential of mRNA technology, spurring investments in developing treatments for cancer, genetic disorders, and infectious diseases. Unlike traditional biologics, mRNA-based drugs rely on synthetic raw materials, eliminating the need for complex cell culture systems and enabling rapid scalability.

The surge in personalized medicine and gene editing therapies has further amplified the demand for high-quality raw materials, as researchers strive to optimize mRNA constructs for enhanced protein expression and immune response modulation. Additionally, the expansion of mRNA-based research beyond vaccines into protein replacement therapies and regenerative medicine has broadened the scope of applications, necessitating stringent quality controls and regulatory-compliant manufacturing processes. As biotechnology companies and CDMOs (Contract Development and Manufacturing Organizations) race to optimize cost-effective and high-yield mRNA production, the focus on raw material innovation, purity standards, and supply chain resilience has become more critical than ever.

What Are the Key Growth Drivers Propelling the mRNA Synthesis Raw Materials Market?

The growth in the mRNA synthesis raw materials market is driven by several factors, including the expansion of mRNA-based therapeutics, increasing investments in biotechnology R&D, and advancements in raw material purification and formulation technologies. The success of mRNA vaccines has fueled research into new applications, including cancer immunotherapy, rare disease treatments, and protein replacement therapies, all of which require specialized raw materials for optimized expression and stability.

The surge in clinical trials involving mRNA-based drugs has also heightened the demand for high-purity nucleotides, enzymatic reagents, and lipid carriers, prompting suppliers to scale up production capabilities. Additionally, the emergence of self-amplifying mRNA (saRNA) and circular RNA (circRNA) technologies has opened new avenues for innovation, driving the need for novel raw material compositions. The growing adoption of AI-driven drug design and high-throughput screening in mRNA formulation development has further accelerated the demand for precision-engineered raw materials. Moreover, the global shift toward decentralized vaccine manufacturing and the rise of CDMOs specializing in nucleic acid therapeutics have strengthened the supply chain, enabling faster production and delivery of mRNA precursors.

The increasing focus on personalized medicine, where mRNA therapies are tailored to individual patients, has also contributed to market expansion, necessitating custom synthesis of modified nucleotides and lipid carriers. As governments and pharmaceutical companies continue to invest in pandemic preparedness and next-generation vaccines, the demand for high-quality, scalable, and regulatory-compliant mRNA raw materials is expected to witness sustained growth, solidifying their role as a cornerstone of modern biotechnology.

What Technological Innovations Are Reshaping the mRNA Synthesis Supply Chain?

Technological advancements have significantly transformed the synthesis and optimization of raw materials required for mRNA production, paving the way for increased efficiency, scalability, and regulatory compliance. One of the most critical breakthroughs has been the optimization of in vitro transcription (IVT) processes, where enzymatic synthesis using bacteriophage RNA polymerases has been fine-tuned to yield higher mRNA purity with minimal double-stranded RNA (dsRNA) contaminants. Improved capping strategies, such as enzymatic capping and co-transcriptional capping using CleanCap technology, have enhanced mRNA stability and translational efficiency.

Additionally, innovations in chemically modified nucleotides, such as N1-methylpseudouridine, have significantly reduced immunogenicity while improving therapeutic efficacy. The lipid nanoparticle (LNP) delivery system has also undergone significant advancements, with ionizable lipids being engineered for greater biocompatibility, targeted tissue delivery, and reduced off-target effects. The automation of nucleoside triphosphate (NTP) synthesis and purification has improved batch-to-batch consistency, reducing production bottlenecks and enabling large-scale mRNA manufacturing.

Furthermore, the integration of AI-driven predictive modeling in formulation design has facilitated rapid optimization of mRNA constructs for different therapeutic applications. These technological improvements have collectively enhanced mRNA yield, stability, and delivery, ensuring that raw materials meet the growing demands of both research institutions and pharmaceutical manufacturers.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Capping Agents segment, which is expected to reach US$711.3 Million by 2030 with a CAGR of a 3.1%. The Nucleotides segment is also set to grow at 2.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $467.8 Million in 2024, and China, forecasted to grow at an impressive 4.7% CAGR to reach $380.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Aldevron, BioNTech SE, Bio-Synthesis Inc., BOC Sciences, Creative Biogene and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Scope of Study:

• Type (Capping Agents, Nucleotides, Plasmid DNA, Enzymes, Other Types)
• Application (Vaccine Production Application, Therapeutics Production Application, Other Applications)
• End-Use (Biopharmaceutical & Pharmaceutical Companies End-Use, CROs & CMOs End-Use, Academic & Research Institutes End-Use)

Key Attributes:

Key Topics Covered:

MARKET OVERVIEW

• Influencer Market Insights
• Tariff Impact on Global Supply Chain Patterns
• mRNA Synthesis Raw Materials - Global Key Competitors Percentage Market Share in 2025 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)

MARKET TRENDS & DRIVERS

• Surge in mRNA Vaccine Development Drives Accelerated Demand for Raw Materials in mRNA Synthesis
• Expanding Investment in Biotechnology and Pharmaceutical R&D Strengthens Market for mRNA Synthesis Raw Materials
• Rising Need for mRNA-Based Therapeutics and Vaccines Expands Market Opportunities for Raw Material Suppliers
• Technological Advancements in mRNA Synthesis Techniques Propel Demand for High-quality Raw Materials
• Increasing Government Funding for mRNA Research and Vaccine Development Generates Growth in Raw Material Requirements
• Expansion of mRNA Vaccine Manufacturing Capacity Strengthens Business Case for Scaling Raw Material Production
• Rising Demand for Personalized Medicine and mRNA Therapies Expands Addressable Market for Synthesis Raw Materials
• Regulatory Support and Accelerated Approval Processes for mRNA Vaccines Increase Raw Material Procurement and Usage
• The Rise in Global Health Initiatives and Vaccination Programs Expands the Market for mRNA Synthesis Raw Materials
• Advancements in Raw Material Purification and Synthesis Technologies Drive Efficiency and Cost Reduction in mRNA Production
• Surge in mRNA-based COVID-19 Vaccine Production Fuels Long-term Demand for mRNA Synthesis Raw Materials
• Growth in Research Institutions and Academic Labs Investing in mRNA Technology Propels Raw Material Demand
• The Emergence of mRNA Therapies Beyond Vaccines Drives Innovation and Expands the Market for Specialized Raw Materials
• Increasing Integration of mRNA Synthesis into Cancer Immunotherapy Research Expands Market Opportunity for Raw Materials
• Expanding Production Facilities for mRNA-Based Products Strengthens Market for Essential Raw Materials in Large-scale Synthesis
• Rising Demand for RNA Modifications and Specialized Reagents Drives New Opportunities for Raw Material Suppliers
• Technological Innovation in Nucleotide Synthesis and Purification Enhances the Quality and Availability of mRNA Raw Materials
• Growing Focus on Sustainable and Cost-effective mRNA Production Methods Expands Market for Raw Materials with Reduced Environmental Impact
• Increasing Competitive Landscape Among Biopharma Companies Strengthens the Demand for Reliable and High-purity Raw Materials
• Growing Collaboration Between mRNA Developers and Raw Material Providers Drives Long-term Supply Chain Stability and Innovation

FOCUS ON SELECT PLAYERS | Some of the 42 companies featured in this mRNA Synthesis Raw Materials report

• Aldevron
• BioNTech SE
• Bio-Synthesis Inc.
• BOC Sciences
• Creative Biogene
• CureVac N.V.
• Eurogentec
• F. Hoffmann-La Roche Ltd.
• HONGENE
• Jena Bioscience GmbH
• Lucigen Corporation
• Maravai LifeSciences
• Merck KGaA
• Moderna, Inc.
• New England Biolabs
• Promega Corporation
• Sigma-Aldrich (MilliporeSigma)
• Thermo Fisher Scientific, Inc.
• TriLink BioTechnologies
• Yeasen Biotechnology (Shanghai) Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/4q30y6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250820767668/en/